20:27 , Oct 12, 2018 |  BioCentury  |  Finance

Spinning out Sitryx

With a $30 million series A round and a pipeline of immunometabolism programs, Sitryx Therapeutics Ltd. became the first start-up to emerge from the Immunology Network at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The round, which closed on...
18:13 , Oct 12, 2018 |  BC Week In Review  |  Financial News

Immunometabolism company Sitryx debuts with GSK ties, $30M

Sitryx Therapeutics Ltd. (Oxford, U.K.) emerged from stealth on Oct. 8 with $30 million from a series A round to develop disease-modifying therapeutics for immuno-oncology and immuno-inflammation, which CEO Neil Weir expects to be enough...
21:37 , Oct 8, 2018 |  BC Extra  |  Financial News

Immunometabolism company Sitryx debuts with GSK ties, $30M

Sitryx Therapeutics Ltd. (Oxford, U.K.) emerged from stealth on Monday with $30 million from a series A round to develop disease-modifying therapeutics for immuno-oncology and immuno-inflammation, which CEO Neil Weir expects to be enough runway...
17:46 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

Twentyeight-Seven Therapeutics Inc. (Cambridge, Mass.) raised $65 million on Sept. 6 in a series A round co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC, Longwood Fund and...
21:22 , Sep 6, 2018 |  BC Extra  |  Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

Twentyeight-Seven Therapeutics Inc. (Cambridge, Mass.) raised $65 million in a series A co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC, Longwood Fund and Astellas Venture Management also...
17:02 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays; high throughput screening A high throughput, CRISPR interference (CRISPRi)-based method of mapping genetic interactions could help identify new drug targets for cancer and genetic disorders. The method involves: selecting sgRNAs against genes identified...
13:22 , Jun 29, 2018 |  BioCentury  |  Finance

Nailing down NLRP3

The next-generation chemistry behind its NLRP3 inhibitors enabled inflammasome play NodThera Ltd. to close a £28 million ($37 million) series A round led by Sofinnova Partners and 5AM Ventures. F-Prime Capital Partners and founding investor...
01:06 , Jan 10, 2018 |  BC Extra  |  Company News

GSK confirms management overhaul

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has replaced about 40% of its top management team since CEO Emma Walmsley took the helm in April 2017, the pharma confirmed to BioCentury Tuesday. GSK spokesperson Sarah Spencer told BioCentury the...
22:05 , Jan 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Candida Cell culture and mouse studies suggest inhibiting Candida MIR1 could help treat azole-resistant oropharyngeal candidiasis. In azole-resistant strains of C. albicans isolated from an HIV-infected patient and in four azole-resistant strains of C. auris,...
21:41 , Nov 30, 2017 |  BC Innovations  |  Strategy

Doctors in the house

While academic partnerships have become par for the course in pharma, GSK is going a step beyond the standard model of external alliances by bringing professors in-house with virtually unrestricted access to its activities. The...